Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Panuveitis Market Size Changed, over the years?
In the past few years, the market size of panuveitis has seen a rapid expansion. It is predicted to increase from $4.05 billion in 2024 to $4.47 billion in 2025, with a compound annual growth rate (CAGR) of 10.5%. The historical growth can be tied to the increased prevalence of autoimmune and infectious diseases, the rising consumption of corticosteroids, the growing preference for biologics, the surging need for ophthalmic imaging, and the recent advancements in research investing in infectious causes.
How Much Will the Panuveitis Market Be Worth in 2029?
Expectations for the panuveitis market size forecast a flurry of accelerated growth in the upcoming years. It is set to expand to $6.58 billion by 2029, with a compound annual growth rate (CAGR) of 10.2%. The forecasted growth is tied to factors such as the widespread adoption of biologic therapies, an increase in personalized medicine demand, a rise in uveitis-related diseases, substantial investments in ophthalmic research, and heightened awareness of the disease. Future trends throughout this forecast period are predicted to involve an increased bias towards biologic therapies, the continued use of sustained-release drug delivery systems, a more significant emphasis on personalized medicine, advancements in AI-aided diagnostics and treatment, along with a surge in minimally invasive surgical techniques.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21244&type=smp
Which is the Largest Company in the Panuveitis Market?
Major companies operating in the panuveitis market are Pfizer Inc., AbbVie, Boehringer Ingelheim International GmbH, Amgen, Teva Pharmaceuticals, Sandoz, Organon group of companies, Zydus Lifesciences Ltd., Mallinckrodt plc, Alvotech, EyePoint Pharmaceuticals Inc., Affibody Medical AB, Alumis Inc., Fujifilm Kyowa Kirin Biologics Co. Ltd., Revolo Biotherapeutics Ltd., Tarsier Pharma, Priovant Therapeutics Inc., Mylan N.V., Clearside Biomedical Inc., pSivida Corp.
What Are the Main Market Drivers in the Panuveitis Industry?
The growth of the panuveitis market is set to be fueled by the increasing occurrence of autoimmune disorders. Autoimmune diseases occur when the immune system mistakenly attacks and harms the body’s own healthy cells and tissues. The surge in autoimmune diseases can be attributed to a mix of genetic susceptibilities, environmental elements like pollution, dietary shifts, and a heightened exposure to certain infections and stressors that could provoke immune system imbalance. Autoimmune disorders encourage progress in panuveitis treatment since they stimulate research into immune system regulation, given that many panuveitis cases are connected to autoimmune activity. For example, the University of Oxford, a prestigious UK research institution, stated in May 2023 that autoimmune disorders impact 10% of the global population, with 13% of women and 7% of men affected. As such, the mounting occurrence of autoimmune disorders is propelling the growth in the panuveitis market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21244&type=smp
How Is the Panuveitis Market Segments Structured?
The panuveitis market covered in this report is segmented –
1) By Type: Infectious Panuveitis, Non-Infectious Panuveitis
2) By Treatment: Pharmacological, Surgical, Phototherapy
3) By Route Of Administration: Oral, Intravitreal, Topical
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Infectious Panuveitis: Bacterial Panuveitis, Viral Panuveitis, Fungal Panuveitis, Parasitic Panuveitis
2) By Non-Infectious Panuveitis: Autoimmune-Related Panuveitis, Idiopathic Panuveitis, Drug-Induced Panuveitis
What Strategic Trends Are Transforming the Panuveitis Market?
Leading firms in the panuveitis market are concentrating on the development of cutting-edge slow-release intravitreal injection formulations for increased patient comfort and improved results. This drug delivery method gradually releases medication in the vitreous humor of the eye, allowing for extended therapeutic effects and less frequent injections. For example, in August 2022, Israel-based Tarsier Pharma revealed it was working on TRS02, a prospective immunomodulator intended to treat retinal diseases. This novel treatment is geared to combat several back-of-the-eye problems marked by innate inflammatory pathologies, such as posterior uveitis (panuveitis) and diabetic macular edema. TRS02, developed from Tarsier’s own technology platform, is in the process of moving towards investigational new drug (IND) submission after successful preclinical benchmarks.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/panuveitis-global-market-report
Which Global Regions Offer the Highest Growth in the Panuveitis Market?
North America was the largest region in the panuveitis market in 2024. The regions covered in the panuveitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21244
This Report Delivers Insight On:
1. How big is the panuveitis market, and how is it changing globally?
2. Who are the major companies in the panuveitis market, and how are they performing?
3. What are the key opportunities and risks in the panuveitis market right now?
4. Which products or customer segments are growing the most in the panuveitis market?
5. What factors are helping or slowing down the growth of the panuveitis market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model